Central Nervous System Therapeutics Market Outlook:
Central Nervous System Therapeutics Market size was valued at USD 139.18 billion in 2025 and is expected to reach USD 268.71 billion by 2035, registering around 6.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of central nervous system therapeutics is evaluated at USD 147.7 billion.
Key Central Nervous System Therapeutics Market Insights Summary:
North America dominates the Central Nervous System Therapeutics Market with a 45.4% share, driven by well-developed healthcare facilities, a rising geriatric population, and the increasing presence of key players, ensuring robust growth through 2026–2035.
The Asia Pacific region is poised for the fastest growth in the Central Nervous System Therapeutics Market from 2026 to 2035, driven by the prevalence of untreated mental health conditions and efforts by WHO and OECD.
The Neurodegenerative segment is expected to hold a 44.1% share by 2035, propelled by the rising prevalence of age-related diseases like Alzheimer’s and Parkinson’s.
Key Growth Trends:
- Development of innovative therapies
- Investments in new drug development
Major Challenges:
- Increase in psychological disorders
- Traditional drug administration
Key Players: Evonik Industries AG, Merck & Co., AstraZeneca, Novartis AG.
Market Size and Growth Projections:
- 2025 Market Size: USD 139.18 billion
- 2026 Market Size: USD 147.7 billion
- Projected Market Size: USD 268.71 billion by 2035
- Growth Forecasts: 6.8% CAGR (2026-2035)
- Largest Region: North America (45.4% Share by 2035)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, Germany, Japan, United Kingdom, France
- Emerging Countries: China, India, Japan, Brazil, Mexico
According to the World Health Organization report published in March 2024, more than 80% of neurological health loss occurs in low- and middle-income nations. The presence of treatment availability varies widely since high-income nations get 70 times more access to neurological professionals per 100,000 people in comparison to middle-income nations. Besides, there are 20 risk factors associated with avoidable neurological circumstances, but dementia, stroke, and idiopathic intellectual disability are common. The World Federation of Neurology in October 2023 stated that the death rate due to stroke is poised to increase by 50%, that is 9.7 million deaths every year, by 2050, hence a potential upliftment in the CNS therapeutics market.
As per the WHO report in July 2023, the Intersectoral Global Action Plan (IGAP) on epilepsy and other neurological diseases is a possible hope for boosting the central nervous system (CNS) therapeutics market development. The plan has ensured five essential strategies- to escalate policy prioritization and expand governance, to ensure timely, effective, and standard diagnosis, to adopt strategies for prevention and promotion, to focus on research and innovation, and expand public health approach. These strategies will only be possible through collaboration between healthcare centers and stakeholders to empower the global population suffering from neurological difficulties.
Central Nervous System Therapeutics Market Growth Drivers and Challenges:
Growth Drivers
- Development of innovative therapies: Penetrating injuries, the effect of explosive waves, and direct impact from external mechanical forces lead to disturbances in the central nervous system. According to DVC Stem, stem cell transplant has a success rate of 60%-70% based on clinical observations, laboratory evaluations, patient reports, long-term follow-ups, and the absence of critical situations. Besides, as published by MDPI in June 2024, surgical and medical treatments, rehabilitation, occupational diagnosis, weight-supported locomotor training (WSLT), and functional electrical stimulation (FES) are other therapies boosting the central nervous system therapeutics market growth.
- Investments in new drug development: According to a report published by MDPI in October 2022, the use of aminoalkylene linker to combine anticholinesterase drug tacrine with antioxidant 2-tolylhydrazinylidene-1,3-diketones resulted in the creation of multifunctional agents which are potential for the treatment of central nervous diseases. Additionally, anti-AChE activity increases the elongation of the alkylene spacer in accordance with molecular docking, resulting in a disease-modifying effect. Thereby, all these chemical combinations are effective in drug evolution to ease CNS disorders, thus a positive impact on the central nervous system therapeutics market.
Challenges
- Increase in psychological disorders: As per the Harvard Medical School research conducted in July 2023, one out of every two people globally develop intellectual dysfunctionality, with approximately 50% of the population suffering by the age of 75 years. These disturbances are caused due to depression, specific anxiety, and post-traumatic stress disorder (PTSD), especially among women. Besides alcohol abuse, depression and phobia are common causes of such disorders among men. All these conditions, if severe in nature, disrupt the brain activity that results in neurological failure, thus a restraint in the growth of the CNS therapeutics market.
- Traditional drug administration: This includes the implementation of plants and natural ingredients to provide treatment to neurological patients. For instance, echinacea, dong quai, ginger, garlic, ginkgo biloba, ginseng, and hypericum perforatum are herbal medicines to overcome disorders. But allergic reactions, headaches, asthma, vomiting, diarrhea, and nausea are a few challenges due to which these herbal medications cannot be consumed. Thereby, the absence of suitable evidence regarding the effectiveness of such medicines is limited, hence another restraint in the upliftment of the central nervous system therapeutics market.
Central Nervous System Therapeutics Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Period |
2026-2035 |
|
CAGR |
6.8% |
|
Base Year Market Size (2025) |
USD 139.18 billion |
|
Forecast Year Market Size (2035) |
USD 268.71 billion |
|
Regional Scope |
|
Central Nervous System Therapeutics Market Segmentation:
By Disease (Neurodegenerative, Neurovascular, Mental Health, CNS Trauma, CNS Cancer, Infectious Diseases)
Based on the disease, the neurodegenerative segment is predicted to capture central nervous system therapeutics market share of over 44.1% by 2035. According to the Cleveland Clinic Organization 2025, this condition destroys and damages parts of the nervous system, especially the brain, and affects people who are aged over 65 years. Dementia, demyelinating diseases, Parkinson's, motor neuron, and prion are different kinds of disorders caused by the condition. A study conducted by Ageing Research Reviews in August 2024 noted that Alzheimer’s disease as a neurotic condition is the sixth leading cause of death with 121,499 deaths in 2019 and globally over 55 million people suffer from dementia. To overcome this, immunotherapy is an ideal approach, utilizing specific antibodies and antigens to extract varying immune responses, hence boosting the central nervous system (CNS) therapeutics market.
Our in-depth analysis of the global market includes the following segments:
|
By Disease |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Central Nervous System Therapeutics Market Regional Analysis:
North America Market Analysis
North America in central nervous system therapeutics market is expected to account for more than 45.4% revenue share by the end of 2035. Factors including well-developed healthcare facilities, a rising geriatric population, and the increasing presence of key players are driving the market growth within the region. As per a report published by the Washington State Department of Health in July 2023, central nervous system stimulants are medications that elevate the activity of norepinephrine and dopamine, resulting in attention, alertness, and energy. For instance, FDA-approved CNS stimulants account for 90% of prescriptions suitable for the treatment of attention-deficit and hyperactivity disorder (ADHD).
The U.S. central nervous system therapeutics market is gaining traction since most people dwell with brain disorders. As stated in the Alzheimer’s Association 2025, almost 7 million people in the U.S. are diagnosed with Alzheimer’s disease. Out of this, approximately 6.9 million belong to the 65-year age group and 73% belong to the 75-year age group and above. Additionally, two-thirds of the U.S. population comprises women suffering from the disease. Thereby, it is projected that by 2050, the patient number will increase to 12.7 million, despite the medical development. Besides, the American Brain Foundation in July 2024 stated that WHO has implemented an action plan to boost brain health and prevent neurological diseases by fostering research, thus positively impacting the market growth.
The central nervous system therapeutics market in Canada is witnessing significant growth owing to the presence of traumatic brain injuries. As disclosed in the Government of Canada 2024 report, concussion is the most common type of such injury, constituting almost 80% to 95%. Moreover, there were 127,460 traumatic-based brain hospitalizations in the region as of 2023, catering to approximately 21,200 per year. Among these, 11% of cases were concussions, 63% were males, 35% were caused due to sports and 29% were due to transport incidents among children, 61% were adults, and 86% were among old patients. To combat this, the Canadian Hospitals Injury Reporting and Prevention Program (CHIRPP) keeps a check on these issues through demographic and healthcare data, thereby uplifting the market growth.
APAC Market Statistics
The central nervous system therapeutics market in Asia Pacific is the fastest-growing region mental health circumstances pose a significant health challenge. As per the OECD report published in December 2024, an estimated 475 million people are affected by such circumstances, accounting for almost one in seven people. Despite the prevalence, there are considerable treatment gaps due to which 90% of the regional population is devoid of appropriate diagnosis. To overcome this, WHO and OECD have taken measures in the form of community-based health services that are accessible. These services provide education and employment, thus reducing stigma, improving treatment results, and ensuring integrated care.
The central nervous system therapeutics market in India is expecting substantial growth owing to geographical and environmental factors leading to the incidence of neurological diseases. As per the Aging and Health Research March 2024 report, Kashmir has a prevalence rate of 14.1 per 100,000 of Parkinson’s disease in comparison to low prevalence in Bangalore and West Bengal with 27/100,000 and 16.1/100,000 of the disease. However, symptomatic treatment is the only possible treatment solution in the country to aid the disease. This treatment aids the symptoms pertaining to sadness, chorea, obsessiveness, irritability, and other behavioral issues. Through this treatment, palliative care is provided, thereby boosting market growth.
The CNS therapeutics market in China is significantly growing due to the presence of brain cancer. According to a gray model study conducted by NLM in April 2024, the incidence of central nervous system tumors in the region will reach 6.1/100000 people by 2030 and the death rate is projected to be 3.1/100000. However, increasing investment in CNS research, focus on health awareness, and improved hospital treatment and diagnosis are solutions to oppose the disorder. For instance, in August 2024, Mubadala Investment Company stated its partnership with CBC Group and acquired ownership of UCB Pharma’s mature business in the region. The purpose was to expand its CNS drug portfolio in China with healthcare at the forefront of the investment strategy.
Key Central Nervous System Therapeutics Market Players:
- Evonik Industries AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co.
- AstraZeneca
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Private Limited
- Pfizer Inc.
Companies dominating the central nervous system therapeutics market are rapidly gaining exposure due to merger and acquisition activities, catering to expand geographic presence and therapeutics capabilities. Additionally, strategic partnerships and licensing deals have gained increasing importance for the purpose of accessing development risks along with emerging markets. For instance, in January 2025, Johnson & Johnson and Intra-Cellular Therapies, Inc. declared an agreement, wherein Johnson & Johnson will cultivate USD 132.00 per share in cash with a total equity of approximately USD 14.6 billion. The purpose is to make enhancement in research for mental diseases, thus innovating therapies for the central nervous system.
Recent Developments
- In December 2024, Noema Pharma expanded its Series B financing by making investments from EQT Life Sciences and raising a capital of USD 147 million. The objective was to provide support for Noema’s Phase 2 clinical trials pertaining to central nervous system disorders with key data readouts.
- In January 2022, Eli Lilly and Company obtained sole rights in Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to statistically study, develop, and make profitable nucleic acid products, targeting the peripheral and central nervous systems.
- Report ID: 7127
- Published Date: Aug 13, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Central Nervous System Therapeutics Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
Copyright @ 2025 Research Nester. All Rights Reserved.
